Navigation Links
Invest in a future without dementia
Date:6/18/2008

Alzheimer's Australia today, released a report 'Australian Dementia Research' that recommends annual funding for dementia research be increased three-fold to $36 million in response to the growing economic and social impact of the dementia epidemic.

Prepared by the Dementia Collaborative Research Centre at the University of NSW, the report concludes that current investment over the last six years in dementia research was about $13 million, 0.6% of the total direct costs of the condition. It recommends investment in dementia research should be maintained at 1.5% of the direct cost of dementia to keep pace with the increasing costs of treatment and care.

By 2030, the total cost to the health care system of dementia is projected to rise to $8.2 billion and the number of people with dementia to double to more than 460,000.

The report concludes that dementia research in Australia is significantly under funded in relation to other chronic diseases. According to 2003 figures, dementia funding is 50% of research funding for cancer, relative to the current disease burden and 30% of research funding for cardiovascular disease, relative to current direct cost of care.

Professor Henry Brodaty, one of the authors of the report, said, "Australian dementia researchers have an excellent track record not withstanding inadequate funding for dementia research."

"The recent initiatives taken by the Federal Government in establishing three Dementia Collaborative Research Centres and a program of dementia grants are encouraging. However, investment in dementia research falls short of what is needed if more effective medical interventions are to be provided to the ever increasing number of people at risk of dementia or with a diagnosis of dementia", he said.

"There is a strong case for dementia to be recognised by the National Health and Medical Research Council as a National Health Priority Area."

Glenn Rees, National Executive Director of Alzheimer's Australia said, "modelling done by Access Economics shows if the onset of Alzheimer's disease could be delayed by five years, it would result in a 50% reduction of new cases each year with a significant saving to the direct cost of dementia".

He said, "This emphasises the importance of research strategies directed to early diagnosis and identifying those at most risk of dementia. In this way Australians will have earlier access to medications currently being trialled that hold out the prospect of modifying the disease."

Projects like the CSIRO Australian Imaging Biomarker and Lifestyle Flagship Study of Ageing (AIBL) "are a strong indication of the potential of Australian research to make a significant contribution to global research in key areas such as early diagnosis and reducing the risk of dementia," he said.

"There is a window of opportunity if investment in research is increased. This will address the issues that the growing numbers of people with dementia will pose for the health system within 15 years".


'/>"/>

Contact: Kaylia Dunstan
61-407-232-212
Research Australia
Source:Eurekalert

Related medicine news :

1. Rutgers scientist receives prestigious Young Investigator Award
2. Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research
3. CIT GAP Funds Invests in OTraces, Inc.
4. Cardiva Medical, Inc. to Present at the Investment In Innovation (In3) Medical Device Summit on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion
5. Digirad Corporation to Present at CapStone Small-Cap Investor Conference
6. Winning Method - Effective Identification and Development of Clinical Investigators
7. Case Western Reserve and Penn State investigators inhibit corneal inflammation
8. LA BioMed investigator wins Distinguished Educator Award
9. New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water
10. Carriage Services Updates Company & Investment Profile
11. White Ribbon Alliance for Safe Motherhood Challenges World Economic Forum on Africa to Invest in Womens Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association for ... speaker Jan Fox will serve as keynote speaker at the organization’s 2016 Spring ... tools to more effectively communicate with their own organizational staff and leadership. ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... will attend the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted ... Greater Columbus Convention Center. , As the longest running and largest worker's ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the strength ... solution that ensures the integrity of biological samples while operating at ultra-high pressures ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Workrite ... based company that has evolved from humble beginnings to being an internationally recognized leader ... company that we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Blood Monitoring & Cardiac Monitoring Devices Market Assessment & Forecast: 2015-2019" ... market for blood monitoring & cardiac monitoring devices was valued at ... 24,830.1 million by 2019 at a CAGR of 6.8% from 2015 ... Europe , Asia-Pacific , Latin ... Africa . The three major factors determining growth of the ...
(Date:2/9/2016)... , Feb. 9, 2016 The life of Dr. ... Center, has been anything but ordinary.  Twists of fate, combined ... War II and the constraints of communist Czechoslovakia to ... he would go on to make history by playing a ... best-selling drugs in the world, Remicade.  Dr. Vilcek brings readers ...
(Date:2/9/2016)... KONG , Feb. 9, 2016 Athenex, Inc. ... Athenex as Vice President of Corporate Strategy and Business Development ... MSc, MBA has joined as Senior Director and Deputy Head of Clinical ... . Simon Pedder stated, "Athenex has ... for a while. Coupled together with their unique business model ...
Breaking Medicine Technology: